Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Net Cash Flow (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Net Cash Flow for 17 consecutive years, with -$3.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 228.57% to -$3.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.6 million, a 237.86% increase, with the full-year FY2025 number at $38.6 million, up 237.86% from a year prior.
  • Net Cash Flow was -$3.6 million for Q4 2025 at Myriad Genetics, down from $71.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $177.2 million in Q3 2021 to a low of -$92.6 million in Q1 2022.
  • A 5-year average of $1.8 million and a median of -$3.6 million in 2023 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 1294.12% in 2025; the steepest drop was 1178.57% in 2025.
  • Myriad Genetics' Net Cash Flow stood at -$36.5 million in 2021, then fell by 23.29% to -$45.0 million in 2022, then surged by 222.67% to $55.2 million in 2023, then crashed by 94.93% to $2.8 million in 2024, then plummeted by 228.57% to -$3.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Net Cash Flow are -$3.6 million (Q4 2025), $71.1 million (Q3 2025), and -$17.9 million (Q2 2025).